JS
Therapeutic Areas
Vistagen Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Fasedienol (PH94B) | Social Anxiety Disorder (SAD) | Phase 3 |
| Itruvone (PH10) | Major Depressive Disorder (MDD) | Phase 2 |
| PH80 | Acute Treatment of Migraine | Preclinical |
| PH15 | Other CNS Disorders | Preclinical |
Leadership Team at Vistagen Therapeutics
SK
Shawn K. Singh, J.D.
Chief Executive Officer and Director
RG
Reid G. Adler, J.D.
Chief Corporate Development Officer and General Counsel
C(
Cynthia (Cindy) Anderson
Chief Financial Officer
MR
Michael R. (Mike) Byrnes
Chief Commercial Officer
LM
Louis Monti, Pharm.D., M.D.
Chief Medical Officer
BD
Bryan D. Olin, Ph.D.
Senior Vice President, Development